10 Best Healthcare Penny Stocks to Buy According to Analysts

Page 9 of 9

1. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Stock Price as of June 27: $1.74

Analyst Upside Potential as of June 27: 474.71%

Number of Hedge Fund Holders as of Q1 2025: 37

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 best healthcare penny stocks to buy according to analysts. Goldman Sachs reiterated its “Buy” rating on Iovance’s stock on June 3. The firm also maintained its $34.00 price target for Iovance shares.

Goldman Sachs based its reaffirmation on new data that Iovance presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO data focused on Amtagvi, a tumor-infiltrating lymphocyte (TIL) therapy. The FDA approved the treatment in February 2024 for adult patients with unresectable or metastatic melanoma. The data supported the therapy’s safety profile, which, according to Goldman Sachs, reinforces Amtagvi’s potential as a significant treatment option.

Goldman Sachs’s analysts noted that the five-year follow-up data are unprecedented for any therapy in this heavily pretreated advanced melanoma population. To them, the data highlights the durability of Amtagvi’s responses. The firm emphasized Amtagvi’s successful US launch, with consistent patient demand, enhanced operations at Authorized Treatment Centers (ATCs), and improved out-of-spec rates (manufacturing quality metrics). It also highlighted the drug’s first full calendar year of sales in 2025 as a key driver.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company. It develops and markets cell therapies that harness a patient’s own immune cells to treat solid tumors. Its lead product is Amtagvi, approved for advanced melanoma, and it also markets Proleukin. Iovance’s pipeline includes candidates for cervical cancer, non-small cell lung cancer, and hematologic malignancies.

While we acknowledge the potential of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IOVA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.

Page 9 of 9